Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart

About this update from Cardiol Therapeutics Inc. Class A

Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with BarchartToronto, Ontario--(Newsfile Corp. - April 14, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that Cardiol's President and Chief Executive Officer, David Elsley, will participate in a live interview on X with Barchart.com ("Barchart") today at 12:00 p.m. EDT.Interview Topics:The ongoing pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditisResults from the recently published Phase II ARCHER trial of CardiolRx™ in acute myocarditisThe Company's next generation drug, CRD-38, in development for heart failureInterview details:Date: April 14, 2026Time: 12:00 PM EDTPlatform: XHost Account on X: @BarchartJoin Live Interview at: x.com/BarchartAfter the event, a full recording of the interview will be available on the Company's X channel (@CardiolRx) and Barchart's (@Barchart).About Cardiol TherapeuticsCardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis.The ARCHER Program is also studying CardiolRx™, specifically in acute myocarditis—an important...

View stock analysis, news, and events for Cardiol Therapeutics Inc. Class A